Rossari Biotech Reports Record Q1 FY27 Revenue and EBITDA; Revenue Rises 28% YoY

What Happened ?

key details

Business Performance:

• Revenue increased 28.2% YoY to ₹697.2 crore, driven by broad-based demand across the core specialty chemicals portfolio.
• All three core business verticals delivered healthy year-on-year growth despite a dynamic operating environment.
• The company’s diversified customer base and product portfolio continued to support stable business momentum.

Segment Performance:

• HPPC: Revenue grew 28% YoY to ₹553 crore.
• TSC: Revenue increased 28% YoY to ₹106 crore.
• AHN: Revenue rose 27% YoY to ₹38 crore.
• HPPC remained the largest contributor, accounting for 79% of consolidated revenue during the quarter.

Core B2B Business:

• Excluding Institutional & B2C businesses, revenue reached ₹626 crore.
• EBITDA improved to ₹85 crore.
• EBITDA margin for the core B2B portfolio stood at 14%, highlighting the strength of Rossari’s underlying specialty chemicals business.

International Expansion:

• Rossari commissioned a greenfield blending facility in Thailand through its subsidiary Unistar Thai.
• The plant has an installed capacity of 5,000 MTPA across powders, granules and liquid formulations.
• The facility is expected to improve customer responsiveness and supply-chain efficiency across Southeast Asia.

Portfolio & Capital Allocation:

• The company completed the sale of its Andheri office, continuing the monetisation of non-core assets.
• This follows the disposal of the Kanjurmarg office in the previous quarter and supports more efficient capital allocation.

Growth Strategy:

• Management continues to focus on improving utilisation of recently created manufacturing capacities.
• Investments in innovation, R&D and differentiated specialty solutions are expected to strengthen the product portfolio and improve operational efficiency over time.
• International expansion and new business development remain important long-term growth drivers. 

Note:

• Rossari Biotech delivered another quarter of broad-based growth supported by its diversified specialty chemicals portfolio and continued international expansion.
• While margin pressure persisted due to higher costs and ongoing investments, the company’s core B2B business remained resilient, positioning it well for sustainable long-term growth.

Risk Analysis

Summary:

• Rossari Biotech delivered record quarterly revenue and EBITDA in Q1 FY27, reflecting strong demand across its specialty chemicals portfolio.
• However, profitability remained under pressure due to higher operating expenses, finance costs, and continued investments in capacity expansion and international growth.
• Sustaining margin expansion while scaling operations will remain a key monitorable for investors.

Key Risks:

• Margin Pressure: EBITDA margin declined to 11.6% from 12.5% in Q1 FY26, while PAT margin contracted to 5.0% from 6.2%, reflecting higher input, employee, finance and depreciation costs. 
• Higher Finance Costs: Finance costs nearly doubled to ₹11.0 crore from ₹5.7 crore in the corresponding quarter last year, which moderated profit growth despite strong revenue expansion. 
• Institutional & B2C Profitability: The Institutional and B2C business remained EBITDA negative during the quarter. Although the company is rationalising the portfolio, improving profitability in this segment remains a key execution challenge. 
• Execution of Expansion Projects: Rossari continues to invest in new manufacturing capabilities and international operations, including its Thailand blending facility. Timely capacity utilisation and successful execution will be essential to generate the expected returns. 
• Global Demand & Export Exposure: The company is expanding its international business, making future performance partly dependent on global demand conditions, customer adoption and export market growth. 

Worst Case:

• If operating costs remain elevated, newly created capacities witness slower-than-expected utilisation, or international demand weakens, revenue growth may not translate into proportional earnings growth, resulting in sustained pressure on margins and return ratios.

Risk Level: Medium

Company Commentary

• Management stated that FY27 began with 28% YoY consolidated revenue growth, supported by strong domestic demand and continued expansion of international operations. 
• The HPPC, TSC and AHN businesses recorded healthy year-on-year growth, driven by deeper market penetration, new applications and increasing contribution from differentiated, value-added specialty solutions. 
• Rossari strengthened its international presence by establishing a greenfield blending facility in Thailand, which is expected to improve customer responsiveness and supply-chain efficiency across Southeast Asia. 
• Management highlighted improving utilisation of investments made in manufacturing capacity, innovation and product development, with a continued focus on operational efficiency and portfolio enhancement. 
• The company reiterated its commitment to disciplined execution, innovation and profitable growth, supported by a healthy balance sheet, integrated manufacturing platform and expanding global footprint.